Tejas, NCT05387837: Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME |
|
|
| Active, not recruiting | 2 | 50 | US | D-4517.2, aflibercept | Ashvattha Therapeutics, Inc. | Neovascular Age-related Macular Degeneration, Diabetic Macular Edema | 11/24 | 12/24 | | |